[Chemotherapy of relapsed AML and ALL].
Nishikawa
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008466:Mechlorethamine / Q000008:administration & dosage; D008942:Mitoxantrone / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011239:Prednisolone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D014747:Vinblastine / Q000008:administration & dosage
D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D011344:Procarbazine; D008466:Mechlorethamine; D014747:Vinblastine; D005047:Etoposide; D011239:Prednisolone; D008942:Mitoxantrone; D001215:Asparaginase; D011241:Prednisone